Avipendekin pegol - Nektar Therapeutics
Alternative Names: NKTR-255; Polymer-conjugated IL-15 - Nektar TherapeuticsLatest Information Update: 28 Jan 2025
At a glance
- Originator Nektar Therapeutics
- Developer AbelZeta Pharma; Fred Hutchinson Cancer Research Center; Gilead Sciences; Janssen; M. D. Anderson Cancer Center; Merck KGaA; Nektar Therapeutics; Stanford University
- Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III B-cell lymphoma; Diffuse large B cell lymphoma
- Phase II Non-small cell lung cancer; Urogenital cancer
- Phase I/II Cervical cancer; Colorectal cancer; Squamous cell cancer
- Preclinical Triple negative breast cancer
- No development reported Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Viral infections
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Burkitt's-lymphoma in USA (Parenteral)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (Parenteral)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Follicular lymphoma in USA (Parenteral)